NY-AGNOVOS-HEALTHCARE
11.1.2022 14:02:11 CET | Business Wire | Press release
AgNovos Healthcare, a developer of new therapies that leverage proprietary, bone-building technology and regenerative medicine to address unmet needs in the treatment of bone disease, announced today the completion of enrollment for its CONFIRM study. CONFIRM is designed to generate additional data supporting the safety and efficacy of the Company’s AGN1 Local Osteo-Enhancement Procedure (LOEP) product when used in post-menopausal women with osteoporosis. With 60 subjects, CONFIRM is the fourth and largest study of LOEP to complete enrollment. This study includes women receiving unilateral or bilateral treatment with the CE-marked AGN1 LOEP kit.
“The completion of patient enrollment in CONFIRM is an important development for the Company.” said Adam Lowe, Senior Vice President of Clinical Research and Quality at AgNovos Healthcare. He continued, “we look forward to completing the collection, analysis and publication of this data.”
Dr. Jo De Schepper is an orthopedic surgeon and principal investigator at the highest enrolling site, AZ Nikolaas in Sint Niklaas, Belgium. He commented, “the response to the study and technology has been very positive. I know my colleagues in orthopedics and metabolic bone health are interested to see this data. We know the impact that fragility fractures associated with osteoporotic bone loss have on our local communities and are encouraged by the promise of this therapeutic approach.”
CONFIRM patients are being enrolled in an extension study to evaluate LOEP’s impact during the five years following treatment.
About AGN1 LOEP Hip Kit
The AGN1 LOEP Hip Kit contains the instruments and materials to perform a minimally invasive procedure to implant AGN1, a proprietary, calcium-based, osteoconductive, and tri-phasic implant material. AGN1 is uniquely formulated with a cell-friendly surface architecture and a resorption profile that enables the rapid formation of new bone. Preclinical and clinical research has shown that AGN1 LOEP treatment delivers immediate, substantial and durable increase in the strength of osteoporotic femurs. The kit is available in select markets under the brand name OSSURE® LOEP kit.
About AgNovos Healthcare
AgNovos Healthcare is a developer of new therapies that leverage proprietary, bone-building technology and regenerative medicine to address unmet needs in the treatment of bone disease. AgNovos Healthcare is privately held and has its corporate headquarters in New York City with manufacturing, research & development, and corporate support services located in Rockville, MD. www.agnovos.com
CAUTION this press release refers to a CE-marked device. The OSSURE Local Osteo-enhancement (LOEP) Kit is not cleared in the United States.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213006012/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCL Group and UpLink Launch Fifth Global Aquapreneur Innovation Challenge to Advance Future Water Systems22.4.2026 13:16:00 CEST | Press release
HCL Group, in partnership with UpLink - the early-stage innovation initiative of the World Economic Forum - has launched the fifth global challenge under the Aquapreneur Innovation Initiative, titled Transforming Water Systems. Applications will be open from 22 April to 4 June 2026. The top 10 winners will receive a total financial award of CHF 1.75 million. For details on eligibility and application criteria, visit: UpLink - Transforming Water Systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421866128/en/ The Aquapreneur Innovation Initiative is a five-year, CHF 15 million collaboration between UpLink, HCL Group, and the World Economic Forum’s Food and Water Initiative, focused on building a global innovation ecosystem for freshwater solutions. Important Dates to Note 22 April to 4 June 2026 Open for submissions July to August 2026 Review and selection process January 2027 Announcement of the winners As water syst
Veristat to Acquire Certara’s Regulatory and Medical Writing Business22.4.2026 13:00:00 CEST | Press release
Strategic acquisition expands and enhances Veristat’s regulatory services to help more clinical trial sponsors develop novel, life-saving therapies across complex disease areas Veristat (the “Company”), a science-first full-service CRO and consultancy that advances complex therapies through the drug development lifecycle to regulatory submission, announced today its intended acquisition of Certara’s Regulatory and Medical Writing business. The team that will join Veristat is known for its white-glove advisory services and deep expertise authoring clinical and non-clinical documents throughout the drug development lifecycle. The acquisition is supported by WindRose Health Investors, LLC, a New York-based healthcare private equity firm, which remains a partner in driving Veristat's growth trajectory and mission. Notably, the acquisition expands Veristat’s regulatory writing and submission capabilities by adding more than 200 industry experts. Combined with the strong track record and mar
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 622.4.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capa
Smartstream Research Reveals Five Realities Redefining Buy-Side Reconciliations22.4.2026 10:05:00 CEST | Press release
Key Facts Over 70% of firms still rely primarily on end-of-day reconciliation, while 53% cite timing differences and data mismatches as the leading causes of breaks. 59% of participants identified external data dependencies as the primary risk, while 47% highlighted internal inconsistencies. And 41% struggle with incomplete or insufficiently enriched data. 69% describe their T+1 model as partially adapted and still evolving. Whilst 41% say T+1 has made data quality a critical priority. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces new findings from its latest industry research report, Smart Reconciliations: The Buy-Side Perspective, highlighting the structural shifts transforming reconciliation, control, and operational confidence across buy-side firms. Based on insights gathered from a roundtable of senior operations leaders across asset management and investment firms, the report identifies five critical re
‘Concrete in Life 2025/26’ Winners Announced – Spectacular Photographs From Around the World22.4.2026 10:00:00 CEST | Press release
Concrete in Life Photo of the Year from the Philippines wins $10,000 top prize Over 20,000 international entries from professional photographers and smartphone amateurs Concrete is the world’s most used substance after water Powerful and striking images from around the world have been chosen as the winners of the Concrete in Life 2025/26 global photography competition, showcasing the essential role concrete plays in daily life, infrastructure, cities, and design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422352135/en/ OVERALL WINNER: Pillars Across the Sea by Celbert Palaganas, Cebu City, Philippines Run by the Global Cement and Concrete Association (GCCA), the annual competition received more than 20,000 entries from professional and amateur photographers, as well as smartphone users, spanning every continent. The competition highlights how concrete supports modern life while also offering moments of beauty, creativ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom